|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
27.74 USD |
+2.86% | +34.92% | +40.24% | |
Published on 05/02/2025 at 04:05
© MT Newswires – 2025
|
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,265,339, According to a Recent SEC Filing |
04:23am |
MT |
|
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,347,335, According to a Recent SEC Filing |
04:05am |
MT |
|
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating |
Apr. 29 |
MT |
|
Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases |
Apr. 29 |
MT |
|
Kiniksa Pharmaceuticals International, plc, Q1 2025 Earnings Call, Apr 29, 2025 |
Apr. 29 |
|
|
Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q1 EPS $0.11, vs. FactSet Est of $0.13 per Share |
Apr. 29 |
MT |
|
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q1 Revenue $137.8M, vs. FactSet Est of $131.9M |
Apr. 29 |
MT |
|
Kiniksa Pharmaceuticals International, plc Revises Financial Guidance for the Full Year 2025 |
Apr. 29 |
CI |
|
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the First Quarter Ended March 31, 2025 |
Apr. 29 |
CI |
|
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $370,475, According to a Recent SEC Filing |
Apr. 23 |
MT |
|
Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target |
Mar. 13 |
MT |
|
Kiniksa Pharmaceuticals International, plc, Q4 2024 Earnings Call, Feb 25, 2025 |
Feb. 25 |
|
|
Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases |
Feb. 25 |
MT |
|
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M |
Feb. 25 |
MT |
|
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss |
Feb. 25 |
MT |
|
Kiniksa Pharmaceuticals International, plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Feb. 25 |
CI |
|
Kiniksa Pharmaceuticals International, plc Provides Earnings Guidance for the Year 2025 |
Feb. 25 |
CI |
|
Kiniksa Pharmaceuticals International, plc Announces Development Program for KPL-387 in Recurrent Pericarditis and Provides an Update on Its Corporate Strategy |
Feb. 25 |
CI |
|
Kiniksa Pharmaceuticals International, plc Provides Revenue Guidance for the Year 2025 |
Jan. 13 |
CI |
|
Kiniksa Pharmaceuticals International, plc Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 01:30 PM |
Jan. 13 |
|
|
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $357,680, According to a Recent SEC Filing |
Nov. 20 |
MT |
|
Kiniksa Pharmaceuticals International, plc, Q3 2024 Earnings Call, Oct 29, 2024 |
24-10-29 |
|
|
Kiniksa Pharmaceuticals Q3 Loss Narrows, Revenue Rises |
24-10-29 |
MT |
|
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Posts Q3 Revenue $112.2M |
24-10-29 |
MT |
|
Kiniksa Pharmaceuticals International, plc Provides Revenue Guidance for 2024 |
24-10-29 |
CI |
KNSA: Dynamic Chart
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.
More about the company
Buy
Average target price
36.57USD
Spread / Average Target
+31.84%
Consensus
Select your edition
All financial news and data tailored to specific country editions
